Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bluejay DiagnosticsBJDX -16.55%35 Return-on-Tangible-Equity is -151.16% as of Mar. 2026. GuruFocus rates BJDX with a GF Score™ of 35/100. Among 758 Medical Devices & Instruments companies, Bluejay Diagnostics ranks worse than 91.29% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bluejay Diagnostics's annualized net income for the quarter that ended in Mar. 2026 was $-7.68 Mil. Bluejay Diagnostics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $5.08 Mil. Therefore, Bluejay Diagnostics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -151.16%.
The historical rank and industry rank for Bluejay Diagnostics's Return-on-Tangible-Equity or its related term are showing as below:
BJDX'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -178.99 Med: -117.02 Max: -43.15
Current: -150.05
During the past 7 years, Bluejay Diagnostics's highest Return-on-Tangible-Equity was -43.15%. The lowest was -178.99%. And the median was -117.02%.
BJDX's Return-on-Tangible-Equity is ranked worse than 91.29% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.055
vs BJDX: -150.05
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bluejay Diagnostics Return-on-Tangible-Equity Related Terms
Bluejay Diagnostics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bluejay Diagnostics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BJDX vs ALURD, VTAK, AMIX: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Bluejay Diagnostics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bluejay Diagnostics Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bluejay Diagnostics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -151.16% mean?
Bluejay Diagnostics (BJDX) has a Return-on-Tangible-Equity of -151.16% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bluejay Diagnostics and its competitors. According to the industry distribution chart, Bluejay Diagnostics ranks #692 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 91.3%.
Is Bluejay Diagnostics' Return-on-Tangible-Equity too high?
Bluejay Diagnostics' current Return-on-Tangible-Equity is -151.16%. Based on the distribution chart, Bluejay Diagnostics ranks #692 out of 758 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bluejay Diagnostics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' Return-on-Tangible-Equity compare to ALURD and VTAK?
According to the Medical Devices & Instruments industry distribution chart, Bluejay Diagnostics ranks #692 out of 758 companies for Return-on-Tangible-Equity. This places Bluejay Diagnostics in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.06, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bluejay Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bluejay Diagnostics's current Return-on-Tangible-Equity is -151.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current Return-on-Tangible-Equity of -151.16%. The current Return-on-Tangible-Equity is -151.16%. Bluejay Diagnostics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current Return-on-Tangible-Equity is -151.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
35GF Score
Get the complete analysis for BJDX
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJDX has been successfully added to your 
